English
简体中文
Total: £ 56.28
Published Date: 2026-03-27 | Pages: 122 | Tables: 124 | Service & Software
The global Human Vaccine Contract Manufacturing market was valued at US$ 7385 million in 2025 and is anticipated to reach US$ 15250 million by 2032, at a CAGR of 11.1% from 2026 to 2032.
The vaccine contract manufacturing sector pertains to the domain where pharmaceutical firms enlist the services of external contract manufacturing entities for the production of vaccines. These contract manufacturing organizations (CMOs) possess the requisite infrastructure, specialized know-how, and dedicated facilities to manufacture vaccines on behalf of the original developers. Contract manufacturers specializing in human use applications are well-equipped to meet the stringent regulatory requirements and quality standards governing vaccine production for human use.
Market CAGR for vaccine contract manufacturing is being driven by the rising vaccination rates worldwide. In the ever-evolving landscape of governmental and healthcare endeavors aimed at bolstering immunization coverage against the backdrop of infectious maladies, a pressing imperative emerges—a dire necessity for the expansion of vaccine production capacity. Within this exigent milieu, contract manufacturers emerge as veritable linchpins, wielding their prowess in the domain of vaccine production to furnish a panacea of flexible and scalable manufacturing solutions. Endowed with specialized facilities and unwavering fidelity to regulatory strictures, these entities furnish pharmaceutical behemoths with the instrumental means to orchestrate a seamless augmentation of vaccine production capabilities. The harrowing specter of the COVID-19 pandemic has served to magnify the imperative of fortifying vaccine manufacturing prowess, propelling a surge in investments geared towards the fecundation of vaccine development and production endeavors. As the apogee of vaccination rates is charted across the global expanse, the clamor for the services rendered by vaccine contract manufacturers is poised to ascend to vertiginous heights, heralding an epoch of unprecedented market growth. Enmeshed within the tapestry of the Vaccine Contract Manufacturing Market are the sinews of global health exigencies, wherein the specter of infectious disease outbreaks and the omnipresent shadow of pandemics serve as vanguards propelling the market's ascension. The burgeoning ubiquity of infectious pathogens, intertwined with the looming specter of bioterrorism, accentuates the exigency of vaccines as sentinels of public health. In this crucible of exigency, contract manufacturers emerge as valiant custodians, orchestrating a symphony of vaccine manufacturing prowess to assuage the tremors of global health crises.
This report delivers a comprehensive overview of the global Human Vaccine Contract Manufacturing market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Human Vaccine Contract Manufacturing. The Human Vaccine Contract Manufacturing market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Human Vaccine Contract Manufacturing market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Human Vaccine Contract Manufacturing manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Lonza
Fujifilm Diosynth Biotechnologies U.S.A., Inc.
Ajinomoto Althea, Inc.
Merck KgaA
Cytovance Biologics
Catalent, Inc.
IDT Biologika GmbH
Albany Molecular Research, Inc.
PRA Health Sciences
ICON plc.
Pharmaceutical Product Development, LLC
Cobra Bio
Paragon Bioservices, Inc.
Emergent BioSolutions Inc.
CSL Limited
BioNTech SE
Wuxi Biologics
Samsung Biologics
Boehringer Ingelheim
Novavax, Inc.
Segment by Type
Attenuated
Inactivated
Subunit-based
Toxoid-based
DNA-based
Segment by Application
Downstream
Upstream
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Human Vaccine Contract Manufacturing companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Attenuated
1.2.3 Inactivated
1.2.4 Subunit-based
1.2.5 Toxoid-based
1.2.6 DNA-based
1.3 Market by Application
1.3.1 Global Human Vaccine Contract Manufacturing Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Downstream
1.3.3 Upstream
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Human Vaccine Contract Manufacturing Market Perspective (2021–2032)
2.2 Global Human Vaccine Contract Manufacturing Growth Trends by Region
2.2.1 Global Human Vaccine Contract Manufacturing Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Human Vaccine Contract Manufacturing Historic Market Size by Region (2021–2026)
2.2.3 Human Vaccine Contract Manufacturing Forecasted Market Size by Region (2027–2032)
2.3 Human Vaccine Contract Manufacturing Market Dynamics
2.3.1 Human Vaccine Contract Manufacturing Industry Trends
2.3.2 Human Vaccine Contract Manufacturing Market Drivers
2.3.3 Human Vaccine Contract Manufacturing Market Challenges
2.3.4 Human Vaccine Contract Manufacturing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Human Vaccine Contract Manufacturing Players by Revenue
3.1.1 Global Top Human Vaccine Contract Manufacturing Players by Revenue (2021–2026)
3.1.2 Global Human Vaccine Contract Manufacturing Revenue Market Share by Players (2021–2026)
3.2 Global Top Human Vaccine Contract Manufacturing Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Human Vaccine Contract Manufacturing Revenue
3.4 Global Human Vaccine Contract Manufacturing Market Concentration Ratio
3.4.1 Global Human Vaccine Contract Manufacturing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human Vaccine Contract Manufacturing Revenue in 2025
3.5 Global Key Players of Human Vaccine Contract Manufacturing Head Offices and Areas Served
3.6 Global Key Players of Human Vaccine Contract Manufacturing, Products and Applications
3.7 Global Key Players of Human Vaccine Contract Manufacturing, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Human Vaccine Contract Manufacturing Breakdown Data by Type
4.1 Global Human Vaccine Contract Manufacturing Historic Market Size by Type (2021–2026)
4.2 Global Human Vaccine Contract Manufacturing Forecasted Market Size by Type (2027–2032)
5 Human Vaccine Contract Manufacturing Breakdown Data by Application
5.1 Global Human Vaccine Contract Manufacturing Historic Market Size by Application (2021–2026)
5.2 Global Human Vaccine Contract Manufacturing Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Human Vaccine Contract Manufacturing Market Size (2021–2032)
6.2 North America Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Human Vaccine Contract Manufacturing Market Size by Country (2021–2026)
6.4 North America Human Vaccine Contract Manufacturing Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Human Vaccine Contract Manufacturing Market Size (2021–2032)
7.2 Europe Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Human Vaccine Contract Manufacturing Market Size by Country (2021–2026)
7.4 Europe Human Vaccine Contract Manufacturing Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Human Vaccine Contract Manufacturing Market Size (2021–2032)
8.2 Asia-Pacific Human Vaccine Contract Manufacturing Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Region (2021–2026)
8.4 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Human Vaccine Contract Manufacturing Market Size (2021–2032)
9.2 Latin America Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Human Vaccine Contract Manufacturing Market Size by Country (2021–2026)
9.4 Latin America Human Vaccine Contract Manufacturing Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Human Vaccine Contract Manufacturing Market Size (2021–2032)
10.2 Middle East & Africa Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2021–2026)
10.4 Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Human Vaccine Contract Manufacturing Introduction
11.1.4 Lonza Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.1.5 Lonza Recent Development
11.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
11.2.1 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Details
11.2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview
11.2.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Introduction
11.2.4 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.2.5 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Development
11.3 Ajinomoto Althea, Inc.
11.3.1 Ajinomoto Althea, Inc. Company Details
11.3.2 Ajinomoto Althea, Inc. Business Overview
11.3.3 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Introduction
11.3.4 Ajinomoto Althea, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.3.5 Ajinomoto Althea, Inc. Recent Development
11.4 Merck KgaA
11.4.1 Merck KgaA Company Details
11.4.2 Merck KgaA Business Overview
11.4.3 Merck KgaA Human Vaccine Contract Manufacturing Introduction
11.4.4 Merck KgaA Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.4.5 Merck KgaA Recent Development
11.5 Cytovance Biologics
11.5.1 Cytovance Biologics Company Details
11.5.2 Cytovance Biologics Business Overview
11.5.3 Cytovance Biologics Human Vaccine Contract Manufacturing Introduction
11.5.4 Cytovance Biologics Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.5.5 Cytovance Biologics Recent Development
11.6 Catalent, Inc.
11.6.1 Catalent, Inc. Company Details
11.6.2 Catalent, Inc. Business Overview
11.6.3 Catalent, Inc. Human Vaccine Contract Manufacturing Introduction
11.6.4 Catalent, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.6.5 Catalent, Inc. Recent Development
11.7 IDT Biologika GmbH
11.7.1 IDT Biologika GmbH Company Details
11.7.2 IDT Biologika GmbH Business Overview
11.7.3 IDT Biologika GmbH Human Vaccine Contract Manufacturing Introduction
11.7.4 IDT Biologika GmbH Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.7.5 IDT Biologika GmbH Recent Development
11.8 Albany Molecular Research, Inc.
11.8.1 Albany Molecular Research, Inc. Company Details
11.8.2 Albany Molecular Research, Inc. Business Overview
11.8.3 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Introduction
11.8.4 Albany Molecular Research, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.8.5 Albany Molecular Research, Inc. Recent Development
11.9 PRA Health Sciences
11.9.1 PRA Health Sciences Company Details
11.9.2 PRA Health Sciences Business Overview
11.9.3 PRA Health Sciences Human Vaccine Contract Manufacturing Introduction
11.9.4 PRA Health Sciences Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.9.5 PRA Health Sciences Recent Development
11.10 ICON plc.
11.10.1 ICON plc. Company Details
11.10.2 ICON plc. Business Overview
11.10.3 ICON plc. Human Vaccine Contract Manufacturing Introduction
11.10.4 ICON plc. Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.10.5 ICON plc. Recent Development
11.11 Pharmaceutical Product Development, LLC
11.11.1 Pharmaceutical Product Development, LLC Company Details
11.11.2 Pharmaceutical Product Development, LLC Business Overview
11.11.3 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Introduction
11.11.4 Pharmaceutical Product Development, LLC Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.11.5 Pharmaceutical Product Development, LLC Recent Development
11.12 Cobra Bio
11.12.1 Cobra Bio Company Details
11.12.2 Cobra Bio Business Overview
11.12.3 Cobra Bio Human Vaccine Contract Manufacturing Introduction
11.12.4 Cobra Bio Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.12.5 Cobra Bio Recent Development
11.13 Paragon Bioservices, Inc.
11.13.1 Paragon Bioservices, Inc. Company Details
11.13.2 Paragon Bioservices, Inc. Business Overview
11.13.3 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Introduction
11.13.4 Paragon Bioservices, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.13.5 Paragon Bioservices, Inc. Recent Development
11.14 Emergent BioSolutions Inc.
11.14.1 Emergent BioSolutions Inc. Company Details
11.14.2 Emergent BioSolutions Inc. Business Overview
11.14.3 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Introduction
11.14.4 Emergent BioSolutions Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.14.5 Emergent BioSolutions Inc. Recent Development
11.15 CSL Limited
11.15.1 CSL Limited Company Details
11.15.2 CSL Limited Business Overview
11.15.3 CSL Limited Human Vaccine Contract Manufacturing Introduction
11.15.4 CSL Limited Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.15.5 CSL Limited Recent Development
11.16 BioNTech SE
11.16.1 BioNTech SE Company Details
11.16.2 BioNTech SE Business Overview
11.16.3 BioNTech SE Human Vaccine Contract Manufacturing Introduction
11.16.4 BioNTech SE Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.16.5 BioNTech SE Recent Development
11.17 Wuxi Biologics
11.17.1 Wuxi Biologics Company Details
11.17.2 Wuxi Biologics Business Overview
11.17.3 Wuxi Biologics Human Vaccine Contract Manufacturing Introduction
11.17.4 Wuxi Biologics Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.17.5 Wuxi Biologics Recent Development
11.18 Samsung Biologics
11.18.1 Samsung Biologics Company Details
11.18.2 Samsung Biologics Business Overview
11.18.3 Samsung Biologics Human Vaccine Contract Manufacturing Introduction
11.18.4 Samsung Biologics Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.18.5 Samsung Biologics Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Details
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Human Vaccine Contract Manufacturing Introduction
11.19.4 Boehringer Ingelheim Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.19.5 Boehringer Ingelheim Recent Development
11.20 Novavax, Inc.
11.20.1 Novavax, Inc. Company Details
11.20.2 Novavax, Inc. Business Overview
11.20.3 Novavax, Inc. Human Vaccine Contract Manufacturing Introduction
11.20.4 Novavax, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021–2026)
11.20.5 Novavax, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Human Vaccine Contract Manufacturing Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Attenuated
Table 3. Key Players of Inactivated
Table 4. Key Players of Subunit-based
Table 5. Key Players of Toxoid-based
Table 6. Key Players of DNA-based
Table 7. Global Human Vaccine Contract Manufacturing Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Human Vaccine Contract Manufacturing Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 9. Global Human Vaccine Contract Manufacturing Market Size by Region (US$ Million), 2021–2026
Table 10. Global Human Vaccine Contract Manufacturing Market Share by Region (2021–2026)
Table 11. Global Human Vaccine Contract Manufacturing Forecasted Market Size by Region (US$ Million), 2027–2032
Table 12. Global Human Vaccine Contract Manufacturing Market Share by Region (2027–2032)
Table 13. Human Vaccine Contract Manufacturing Market Trends
Table 14. Human Vaccine Contract Manufacturing Market Drivers
Table 15. Human Vaccine Contract Manufacturing Market Challenges
Table 16. Human Vaccine Contract Manufacturing Market Restraints
Table 17. Global Human Vaccine Contract Manufacturing Revenue by Players (US$ Million), 2021–2026
Table 18. Global Human Vaccine Contract Manufacturing Market Share by Players (2021–2026)
Table 19. Global Top Human Vaccine Contract Manufacturing Players by Tier (Tier 1, Tier 2, and Tier 3), based on Human Vaccine Contract Manufacturing Revenue, 2025
Table 20. Ranking of Global Top Human Vaccine Contract Manufacturing Companies by Revenue (US$ Million) in 2025
Table 21. Global 5 Largest Players Market Share by Human Vaccine Contract Manufacturing Revenue (CR5 and HHI), 2021–2026
Table 22. Global Key Players of Human Vaccine Contract Manufacturing, Headquarters and Area Served
Table 23. Global Key Players of Human Vaccine Contract Manufacturing, Products and Applications
Table 24. Global Key Players of Human Vaccine Contract Manufacturing, Date of General Availability (GA)
Table 25. Mergers and Acquisitions, Expansion Plans
Table 26. Global Human Vaccine Contract Manufacturing Market Size by Type (US$ Million), 2021–2026
Table 27. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2021–2026)
Table 28. Global Human Vaccine Contract Manufacturing Forecasted Market Size by Type (US$ Million), 2027–2032
Table 29. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2027–2032)
Table 30. Global Human Vaccine Contract Manufacturing Market Size by Application (US$ Million), 2021–2026
Table 31. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2021–2026)
Table 32. Global Human Vaccine Contract Manufacturing Forecasted Market Size by Application (US$ Million), 2027–2032
Table 33. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2027–2032)
Table 34. North America Human Vaccine Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. North America Human Vaccine Contract Manufacturing Market Size by Country (US$ Million), 2021–2026
Table 36. North America Human Vaccine Contract Manufacturing Market Size by Country (US$ Million), 2027–2032
Table 37. Europe Human Vaccine Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 38. Europe Human Vaccine Contract Manufacturing Market Size by Country (US$ Million), 2021–2026
Table 39. Europe Human Vaccine Contract Manufacturing Market Size by Country (US$ Million), 2027–2032
Table 40. Asia-Pacific Human Vaccine Contract Manufacturing Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 41. Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Region (US$ Million), 2021–2026
Table 42. Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Region (US$ Million), 2027–2032
Table 43. Latin America Human Vaccine Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Latin America Human Vaccine Contract Manufacturing Market Size by Country (US$ Million), 2021–2026
Table 45. Latin America Human Vaccine Contract Manufacturing Market Size by Country (US$ Million), 2027–2032
Table 46. Middle East & Africa Human Vaccine Contract Manufacturing Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 47. Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (US$ Million), 2021–2026
Table 48. Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (US$ Million), 2027–2032
Table 49. Lonza Company Details
Table 50. Lonza Business Overview
Table 51. Lonza Human Vaccine Contract Manufacturing Product
Table 52. Lonza Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 53. Lonza Recent Development
Table 54. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Details
Table 55. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview
Table 56. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product
Table 57. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 58. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Development
Table 59. Ajinomoto Althea, Inc. Company Details
Table 60. Ajinomoto Althea, Inc. Business Overview
Table 61. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product
Table 62. Ajinomoto Althea, Inc. Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 63. Ajinomoto Althea, Inc. Recent Development
Table 64. Merck KgaA Company Details
Table 65. Merck KgaA Business Overview
Table 66. Merck KgaA Human Vaccine Contract Manufacturing Product
Table 67. Merck KgaA Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 68. Merck KgaA Recent Development
Table 69. Cytovance Biologics Company Details
Table 70. Cytovance Biologics Business Overview
Table 71. Cytovance Biologics Human Vaccine Contract Manufacturing Product
Table 72. Cytovance Biologics Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 73. Cytovance Biologics Recent Development
Table 74. Catalent, Inc. Company Details
Table 75. Catalent, Inc. Business Overview
Table 76. Catalent, Inc. Human Vaccine Contract Manufacturing Product
Table 77. Catalent, Inc. Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 78. Catalent, Inc. Recent Development
Table 79. IDT Biologika GmbH Company Details
Table 80. IDT Biologika GmbH Business Overview
Table 81. IDT Biologika GmbH Human Vaccine Contract Manufacturing Product
Table 82. IDT Biologika GmbH Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 83. IDT Biologika GmbH Recent Development
Table 84. Albany Molecular Research, Inc. Company Details
Table 85. Albany Molecular Research, Inc. Business Overview
Table 86. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product
Table 87. Albany Molecular Research, Inc. Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 88. Albany Molecular Research, Inc. Recent Development
Table 89. PRA Health Sciences Company Details
Table 90. PRA Health Sciences Business Overview
Table 91. PRA Health Sciences Human Vaccine Contract Manufacturing Product
Table 92. PRA Health Sciences Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 93. PRA Health Sciences Recent Development
Table 94. ICON plc. Company Details
Table 95. ICON plc. Business Overview
Table 96. ICON plc. Human Vaccine Contract Manufacturing Product
Table 97. ICON plc. Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 98. ICON plc. Recent Development
Table 99. Pharmaceutical Product Development, LLC Company Details
Table 100. Pharmaceutical Product Development, LLC Business Overview
Table 101. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product
Table 102. Pharmaceutical Product Development, LLC Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 103. Pharmaceutical Product Development, LLC Recent Development
Table 104. Cobra Bio Company Details
Table 105. Cobra Bio Business Overview
Table 106. Cobra Bio Human Vaccine Contract Manufacturing Product
Table 107. Cobra Bio Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 108. Cobra Bio Recent Development
Table 109. Paragon Bioservices, Inc. Company Details
Table 110. Paragon Bioservices, Inc. Business Overview
Table 111. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product
Table 112. Paragon Bioservices, Inc. Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 113. Paragon Bioservices, Inc. Recent Development
Table 114. Emergent BioSolutions Inc. Company Details
Table 115. Emergent BioSolutions Inc. Business Overview
Table 116. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product
Table 117. Emergent BioSolutions Inc. Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 118. Emergent BioSolutions Inc. Recent Development
Table 119. CSL Limited Company Details
Table 120. CSL Limited Business Overview
Table 121. CSL Limited Human Vaccine Contract Manufacturing Product
Table 122. CSL Limited Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 123. CSL Limited Recent Development
Table 124. BioNTech SE Company Details
Table 125. BioNTech SE Business Overview
Table 126. BioNTech SE Human Vaccine Contract Manufacturing Product
Table 127. BioNTech SE Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 128. BioNTech SE Recent Development
Table 129. Wuxi Biologics Company Details
Table 130. Wuxi Biologics Business Overview
Table 131. Wuxi Biologics Human Vaccine Contract Manufacturing Product
Table 132. Wuxi Biologics Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 133. Wuxi Biologics Recent Development
Table 134. Samsung Biologics Company Details
Table 135. Samsung Biologics Business Overview
Table 136. Samsung Biologics Human Vaccine Contract Manufacturing Product
Table 137. Samsung Biologics Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 138. Samsung Biologics Recent Development
Table 139. Boehringer Ingelheim Company Details
Table 140. Boehringer Ingelheim Business Overview
Table 141. Boehringer Ingelheim Human Vaccine Contract Manufacturing Product
Table 142. Boehringer Ingelheim Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 143. Boehringer Ingelheim Recent Development
Table 144. Novavax, Inc. Company Details
Table 145. Novavax, Inc. Business Overview
Table 146. Novavax, Inc. Human Vaccine Contract Manufacturing Product
Table 147. Novavax, Inc. Revenue in Human Vaccine Contract Manufacturing Business (US$ Million), 2021–2026
Table 148. Novavax, Inc. Recent Development
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
Table 152. Authors List of This Report
List of Figures
Figure 1. Human Vaccine Contract Manufacturing Picture
Figure 2. Global Human Vaccine Contract Manufacturing Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Human Vaccine Contract Manufacturing Market Share by Type: 2025 vs 2032
Figure 4. Attenuated Features
Figure 5. Inactivated Features
Figure 6. Subunit-based Features
Figure 7. Toxoid-based Features
Figure 8. DNA-based Features
Figure 9. Global Human Vaccine Contract Manufacturing Market Size by Application (US$ Million), 2021–2032
Figure 10. Global Human Vaccine Contract Manufacturing Market Share by Application: 2025 vs 2032
Figure 11. Downstream Case Studies
Figure 12. Upstream Case Studies
Figure 13. Human Vaccine Contract Manufacturing Report Years Considered
Figure 14. Global Human Vaccine Contract Manufacturing Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 15. Global Human Vaccine Contract Manufacturing Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Human Vaccine Contract Manufacturing Market Share by Region: 2025 vs 2032
Figure 17. Global Human Vaccine Contract Manufacturing Market Share by Players in 2025
Figure 18. Global Human Vaccine Contract Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by Human Vaccine Contract Manufacturing Revenue in 2025
Figure 20. North America Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. North America Human Vaccine Contract Manufacturing Market Share by Country (2021–2032)
Figure 22. United States Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Canada Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Human Vaccine Contract Manufacturing Market Share by Country (2021–2032)
Figure 26. Germany Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. France Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. U.K. Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Italy Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Russia Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Ireland Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Human Vaccine Contract Manufacturing Market Share by Region (2021–2032)
Figure 34. China Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Japan Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. South Korea Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Southeast Asia Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. India Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Australia & New Zealand Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Human Vaccine Contract Manufacturing Market Share by Country (2021–2032)
Figure 42. Mexico Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Brazil Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Human Vaccine Contract Manufacturing Market Share by Country (2021–2032)
Figure 46. Israel Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Saudi Arabia Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. UAE Human Vaccine Contract Manufacturing Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Lonza Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 50. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 51. Ajinomoto Althea, Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 52. Merck KgaA Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 53. Cytovance Biologics Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 54. Catalent, Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 55. IDT Biologika GmbH Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 56. Albany Molecular Research, Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 57. PRA Health Sciences Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 58. ICON plc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 59. Pharmaceutical Product Development, LLC Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 60. Cobra Bio Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 61. Paragon Bioservices, Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 62. Emergent BioSolutions Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 63. CSL Limited Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 64. BioNTech SE Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 65. Wuxi Biologics Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 66. Samsung Biologics Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 67. Boehringer Ingelheim Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 68. Novavax, Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021–2026)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
